ID: ALA5280275

Max Phase: Preclinical

Molecular Formula: C44H45Cl2N5O5

Molecular Weight: 794.78

Associated Items:

Representations

Canonical SMILES:  CN1CCCN[C@@H](Cc2ccc(Cl)cc2)CC(=O)N[C@H]2CCc3ccccc3N(CC(=O)N[C@H](Cc3ccc(Cl)c(-c4cc5ccccc5o4)c3)CC1=O)C2=O

Standard InChI:  InChI=1S/C44H45Cl2N5O5/c1-50-20-6-19-47-33(21-28-11-15-32(45)16-12-28)25-41(52)49-37-18-14-30-7-2-4-9-38(30)51(44(37)55)27-42(53)48-34(26-43(50)54)22-29-13-17-36(46)35(23-29)40-24-31-8-3-5-10-39(31)56-40/h2-5,7-13,15-17,23-24,33-34,37,47H,6,14,18-22,25-27H2,1H3,(H,48,53)(H,49,52)/t33-,34+,37-/m0/s1

Standard InChI Key:  AGLNRYYTWNTFOQ-UEHMVRIRSA-N

Associated Targets(Human)

BCL2/BCL2L11 33 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Induced myeloid leukemia cell differentiation protein Mcl-1 3820 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Induced myeloid leukemia cell differentiation protein Mcl-1/Bcl-2-like protein 11 104 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 794.78Molecular Weight (Monoisotopic): 793.2798AlogP: 6.74#Rotatable Bonds: 5
Polar Surface Area: 123.99Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: 2HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.32CX Basic pKa: 7.45CX LogP: 5.63CX LogD: 5.30
Aromatic Rings: 5Heavy Atoms: 56QED Weighted: 0.18Np Likeness Score: -0.04

References

1. Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, Keefe AD, Lamb ML, Lan H, Li Y, Ma H, Mlynarski S, Packer MJ, Rawlins PB, Robbins DW, Shen H, Sigel EA, Soutter HH, Su N, Troast DM, Wang H, Wickson KF, Wu C, Zhang Y, Zhao Q, Zheng X, Hird AW..  (2017)  Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.,  (2): [PMID:28197319] [10.1021/acsmedchemlett.6b00464]

Source